• Home
  • Search Results
  • Replication stress conferred by POT1 dysfunction promotes telomere relocalization to the nuclear pore.

Replication stress conferred by POT1 dysfunction promotes telomere relocalization to the nuclear pore.

Genes & development (2020-10-31)
Alexandra M Pinzaru, Mike Kareh, Noa Lamm, Eros Lazzerini-Denchi, Anthony J Cesare, Agnel Sfeir
ABSTRACT

Mutations in the telomere-binding protein POT1 are associated with solid tumors and leukemias. POT1 alterations cause rapid telomere elongation, ATR kinase activation, telomere fragility, and accelerated tumor development. Here, we define the impact of mutant POT1 alleles through complementary genetic and proteomic approaches based on CRISPR interference and biotin-based proximity labeling, respectively. These screens reveal that replication stress is a major vulnerability in cells expressing mutant POT1, which manifests as increased telomere mitotic DNA synthesis at telomeres. Our study also unveils a role for the nuclear pore complex in resolving replication defects at telomeres. Depletion of nuclear pore complex subunits in the context of POT1 dysfunction increases DNA damage signaling, telomere fragility and sister chromatid exchanges. Furthermore, we observed telomere repositioning to the nuclear periphery driven by nuclear F-actin polymerization in cells with POT1 mutations. In conclusion, our study establishes that relocalization of dysfunctional telomeres to the nuclear periphery is critical to preserve telomere repeat integrity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
LookOut® Mycoplasma PCR Detection Kit, Optimized for use with JumpStart Taq DNA Polymerase, D9307.
Sigma-Aldrich
Dextrose, meets EP, BP, JP, USP testing specifications, anhydrous
Sigma-Aldrich
JumpStart Taq DNA Polymerase, with MgCl2
Sigma-Aldrich
Anti-PICH Antibody, clone 142-26-3, clone 142-26-3, from mouse
Sigma-Aldrich
Anti-NUP58 antibody produced in rabbit, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
MISSION® esiRNA, targeting human WAPL